Status:
COMPLETED
Improvement the Anti-migraine Treatment Efficacy by Tailoring the Drug to Individual's Pain Modulation Profile
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Pain
Eligibility:
FEMALE
18-50 years
Phase:
NA
Brief Summary
* To delineate brain mechanisms that subserve endogenous analgesic (EA) in the healthy state. * To identify alterations in mechanisms supporting EA in chronic pain (migraine) and their therapeutic rel...
Detailed Description
The proposed research will use psychophysics and multiparametric MRI to (i) delineate the brain mechanisms that subserve and regulate endogenous analgesia (EA)in the healthy state and (ii) to identify...
Eligibility Criteria
Inclusion
- healthy females
- migaine females
- ages 18-50
- for migraineurs: \>4 attacks/month
Exclusion
- any migraine preventive treatment received during last 3 months or prior treatment with amytriptiline
- other chronic pain conditions
- psychiatric, other neurological diseases, language barrier or cognitive dysfunction
- Patients and controls will be asked to withdraw from any pain-relieving medications for 24 hours before the testing. The tests will be performed interictally atleast 2 days after the last attack.
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01470339
Start Date
December 1 2011
End Date
July 1 2014
Last Update
September 17 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MRI center
Haifa, Israel